A bioequivalency study of novel levetiracetam extended release 1500 mg tablets under fasing/non fasting swithcover conditions in heathy subjects.

Trial Profile

A bioequivalency study of novel levetiracetam extended release 1500 mg tablets under fasing/non fasting swithcover conditions in heathy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 May 2017 New trial record
    • 28 Apr 2017 Results assessing bioequivalence using patient data from this and other two trials (see CTPs 284435 and 284433), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top